Rockwell Medical, Inc. · NASDAQ:RMTI

Rockwell Medical — Investor Presentation (April 2023)

18 slides from Rockwell Medical's investor presentation, Apr 10, 2023

  1. Slide 1: Investor Presentation

    ©) ROCKWELL MEDICAL Investor Presentation April 1, 2023 RMTI Nasdaq Listec

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, reliance on capital investments,

  3. Slide 3: Rockwell Medical At A Glance

    Rockwell Medical At A Glance Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide Business Second largest supplier of acid and bicarbonate concentrates for dialysis patients i Overview Restructured busin

  4. Slide 4: Executive Management Team

    Executive Management Team Mark Strobeck, Ph.D. President and CEO Aquigo. Asserno= () sR One TOLAZ, Tim T. Chole SVP, Sales and Marketing Baxter ( Cochhear Paul E. McGarry, CPA SVP, Finance and Chief Accounting Officer oe Alyvant Gersseions Deloitte & Touche Marc Hoffman, M.D. SVP, Chief Medical Offi

  5. Slide 5: Corporate Strategy

    Corporate Strategy QO) Be the Global Leader in Hemodialysis Concentrates ) Provide Customers with the Highest Quality and Most Reliable Products and Services O) Achieve Profitability and $100M+ Annual Revenue QO) Focus on Innovative, Long-Term Growth Opportunities © 2023 Rockwell Medical, Inc (©) RO

  6. Slide 6: What is Hemodialysis?

    What is Hemodialysis? * Procedure whereby a dialysis machine and a special filter called an artificial kidney — or dialyzer — are used to clean a patient’s blood. * Filters out wastes, salts, and excess fluid, and corrects electrolyte and acid-base imbalances for people who have kidney failure, or e

  7. Slide 7: U.S. In-Center Hemodialysis Concentrates Market

    U.S. In-Center Hemodialysis Concentrates Market Growth driven primarily by the increasing number of patients suffering from end-stage kidney disease TODAY 2026 SOURCE: “Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022) RMTI © 2023 Rocwel Medial, (ROCKWELL Nasdag Li

  8. Slide 8: Indispensable Player in a Large and Expanding Market

    Indispensable Player in a Large and Expanding Market * Rockwell Medical currently serves 1700+ dialysis clinics and growing. * Rockwell Medical is one of two manufacturers and suppliers that has scalability and transportation infrastructure to service the 7,200+ dialysis clinics in the U.S., along w

  9. Slide 9: Geographic Expansion and New Growth Opportunities

    Geographic Expansion To-date, Rockwell has been geographically concentrated in the East, South, Midwest Currently, one large primary supplier in the West Represents approximately a $100M opportunity Focus in 2023 on accessing West through acquisition or opening new facility New Growth Opportunities

  10. Slide 10: International Partnerships

    © ROCKWELL MEDICAL International Partnerships

  11. Slide 11: Ferric Pyrophosphate Citrate (FPC) Platform

    Ferric Pyrophosphate Citrate (FPC) Platform Indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis- dependent chronic kidney disease a4 Bypasses the liver, delivers iron directly to circulating transferrin? TRIFERIC Internationally + Expect royalties from ou

  12. Slide 12: FPC Development Pipeline

    FPC Development Pipeline Prhases [phase | phase3 | submites | approved | commercial | partners | Hb Maintenance in Dialysis Patients 0 Es i wanaanc TRIFERIC® AVNU (LV.) China —— Qua BUSES Development work on Hold SS Gere BioRenal SpA TRIFERIC® AVNU (1.V.) Chile BRSSEET TIT | Home Infusion _ FPC for

  13. Slide 13: Financials and Milestones

    © ROCKWELL MEDICAL Financials and Milestones

  14. Slide 14: Delivering on New Business Strategy

    Delivering on New Business Strategy Achieved three consecutive quarters of improved financial performance, highest quarterly revenue to-date Three Months Ended (In Thousands, Except Per Share Amounts) Net Sales 15,333 16,124 18,682 Operating Cash Flows $ (9,026) $ (9,812) $ (5,906) Net Loss $ (8941)

  15. Slide 15: Focused on Driving Business to Profitability in 2024

    Focused on Driving Business to Profitability in 2024 .. along with revenue growth, reducing expenses and paying down debt 85 75 70 78.0 — 82.0 2023 GUIDANCE Cash and cash equivalents at December 31, 2022 was $21.5 million * The Loan and Security Agreement with Innovatus Life Sciences Lending Fund |,

  16. Slide 16: Milestones

    23 Milestones Complete 100% Transfer of Baxter Business with Preferred Economics Expand Partnerships with Existing Hemodialysis Customers Grow Concentrates Business by Adding New Customers Distribute Hemodialysis Products in New Geographies Increase TRIFERIC® Sales in Korea (Jeil Pharmaceutical) Dri

  17. Slide 17: Why Invest in Rockwell Medical?

    Why Invest in Rockwell Medical? C) Revenue-Generating Business CQ) Path Toward Growth and Profitability O) Strengthened Financial Position L) De-Risked Clinical Development and Regulatory Path LJ No Additional Fundraising Anticipated in Order to Achieve Profitability Q) Attractive Valuation © 2023 R

  18. Slide 18: MEDICAL

    ©) ROCKWELL MEDICAL www.rockwellmed.com IR@rockwellmed.com

Rockwell Medical — Investor Presentation (April 2023) on 6ix